FrancophonIA/ELRC3.0 huggingface dataset:
English: Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets).
Croatian: Descovy dolazi u bocama od 30 tableta (sa sredstvom za sušenje od silika gela koje se mora čuvati u boci radi zaštite tableta).
English: Treatment difference
Croatian: Razlika u liječenju
English: Patients were stratified by the class of the third agent in their prior treatment regimen.
Croatian: Bolesnici su bili stratificirani ovisno o skupini trećeg lijeka u njihovom prethodnom režimu liječenja.
English: Therefore, Descovy should not be used during breast-feeding.
Croatian: Stoga se Descovy ne smije primjenjivati tijekom dojenja.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Descovy in one or more subsets of the paediatric population in the treatment of HIV-1 infection (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Descovy u jednoj ili više podskupina pedijatrijske populacije za liječenje infekcije HIV-1 (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves.
Croatian: To je djelomično povezano s poboljšanim zdravljem i načinom života, dok je u slučaju lipida u krvi katkad povezano i sa samim lijekovima za liječenje HIV-a.
English: • Autoimmune disorders (the immune system attacks healthy body tissue), may also occur after you start taking medicines for HIV infection.
Croatian: • Autoimuni poremećaji (imunološki sustav napada zdravo tkivo Vašeg organizma), mogu se također dogoditi nakon početka uzimanja lijekova za liječenje infekcije HIV-om.
English: There is insufficient information on the effects of emtricitabine and tenofovir in newborns/infants.
Croatian: Nema dovoljno podataka o učincima emtricitabina i tenofovira na novorođenčad/dojenčad.
English: No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2).
Croatian: Nije potrebna prilagodba doze lijeka Descovy u starijih bolesnika (vidjeti dijelove 5.1 i 5.2).
English: The safety of emtricitabine and tenofovir alafenamide has not been established in these patients.
Croatian: Sigurnost emtricitabina i tenofoviralafenamida u tih bolesnika nije ustanovljena.
English: It is recommended that you do not breast-feed to avoid passing the virus to the baby through breast milk.
Croatian: Preporučuje se da ne dojite kako bi se izbjegla mogućnost da virus preko majčinog mlijeka prijeđe na dojenče.
English: It is important not to miss a dose of Descovy.
Croatian: Važno je da ne propustite uzeti dozu lijeka Descovy.
English: Pooled treatment outcomes at 48 and 144 weeks are shown in Table 4.
Croatian: Objedinjeni ishodi liječenja u 48 i 144 tjedana prikazani su u Tablici 4.
English: Patients co-infected with HIV and HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
Croatian: Bolesnike istodobno zaražene HIV-om i HBV-om koji prekinu liječenje lijekom Descovy mora se pažljivo pratiti uz kliničku i laboratorijsku kontrolu tijekom najmanje nekoliko mjeseci nakon prekida liječenja.
English: 1 When doses are provided, they are the doses used in clinical drug-drug interaction studies.
Croatian: 1 Kada su doze navedene, radi se o dozama koje su primijenjene u kliničkim ispitivanjima interakcija lijekova.
English: There are no data on fertility from the use of Descovy in humans.
Croatian: Nema podataka o plodnosti pri primjeni lijeka Descovy u ljudi.
English: If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets.
Croatian: Ako zbog bilo kojeg razloga prestanete uzimati lijek Descovy, porazgovarajte s liječnikom prije nego što ponovno počnete uzimati tablete lijeka Descovy.
English: Tipranavir/ritonavir results in P-gp induction.
Croatian: Tipranavir/ritonavir izazivaju indukciju P-gp-a.
English: In some patients with advanced HIV infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started.
Croatian: U nekih bolesnika s uznapredovalom HIV-bolešću (SIDA) i koji su imali oportunističke infekcije (infekcije koje nastaju u osoba sa slabim imunološkim sustavom) mogu se pojaviti znakovi i simptomi upale od prethodnih infekcija ubrzo nakon početka antiretrovirusnog liječenja.
English: No dose adjustment of midazolam is required.
Croatian: Nije potrebna prilagodba doze midazolama.
English: In these 2 patients, no amino acid substitutions associated with resistance to any of the components of E/C/F/TAF were identified in HIV-1 or HBV.
Croatian: U ta 2 bolesnika, supstitucije aminokiselina povezane s rezistencijom na bilo koji sastojak E/C/F/TAF-a nisu utvrđene u HIV 1 ili HBV.
English: No dose adjustment of sertraline is required.
Croatian: Nije potrebna prilagodba doze sertralina.
English: The use of Descovy in children aged 11 years or under has not yet been studied.
Croatian: Primjena lijeka Descovy u djece u dobi od 11 godina i mlađoj još nije ispitana.
English: HIV-1 RNA
Croatian: HIV-1 RNK
English: The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.
Croatian: Sigurnost i djelotvornost primjene lijeka Descovy u bolesnika istodobno zaraženih virusom HIV-1 i virusom hepatitisa C (HCV) nisu ustanovljene.
English: Patients receiving Descovy or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and, therefore, should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Croatian: U bolesnika koji primaju lijek Descovy ili neku drugu antiretrovirusnu terapiju mogu se i dalje razvijati oportunističke infekcije i druge komplikacije infekcije HIV-om, pa bi stoga morali ostati pod strogim kliničkim nadzorom liječnika koji imaju iskustva u liječenju bolesnika s bolestima povezanim s HIV-om.
English: What you need to know before you take Descovy Do not take Descovy:
Croatian: Što morate znati prije nego počnete uzimati lijek Descovy Nemojte uzimati lijek Descovy:
English: Virologic success rates at Week 48 were: Descovy Containing Regimen: 89.7% (227 of 253 subjects); Abacavir/lamivudine Containing Regimen: 92.7%% (230 of 248 subjects).
Croatian: Stope virološkog uspjeha u 48. tjednu bile su sljedeće: režim koji je sadržavao lijek Descovy: 89,7% (227 od 253 ispitanika); režim koji je sadržavao abakavir/lamivudin: 92,7% (230 od 248 ispitanika).
English: Stopping Descovy can seriously affect how well future treatment works.
Croatian: Prestanak uzimanja lijeka Descovy može ozbiljno utjecati na djelotvornost budućeg liječenja.
English: If you take more than the recommended dose of Descovy you may be at higher risk of side effects of this medicine (see section 4, Possible side effects).
Croatian: Ako uzmete više od preporučene doze lijeka Descovy, može Vam se povećati rizik od nuspojava ovog lijeka (pogledajte dio 4, Moguće nuspojave).
English: Third agent in HIV treatment regimen (see section 4.5)
Croatian: Treći lijek u režimu liječenja HIV-a (vidjeti dio 4.5)
English: The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2).
Croatian: Sigurnost i djelotvornost primjene lijeka Descovy u bolesnika sa značajnim podležećim bolestima jetre nisu ustanovljene (vidjeti dijelove 4.2 i 5.2).
English: Some patients taking combination antiretroviral medicines such as Descovy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone).
Croatian: Neki bolesnici koji uzimaju kombinirane antiretrovirusne lijekove kao što je Descovy mogu razviti bolest kostiju koja se zove osteonekroza (odumiranje koštanog tkiva prouzrokovano gubitkom prokrvljenosti kosti).
English: Medicines used in treating hepatitis B infection:
Croatian: Lijekovi za liječenje infekcije virusom hepatitisa B:
English: The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.
Croatian: Na distribuciju tenofoviralafenamida u tijelu može utjecati aktivnost OATP1B1 i OATP1B3.
English: Do not stop taking Descovy
Croatian: Nemojte prestati uzimati lijek Descovy
English: Other medicines and Descovy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable
Croatian: E/C/F/TAF =elvitegravir/kobicistat/emtricitabin/tenofoviralafenamidfumarat FTC = emtricitabin; TAF = tenofoviralafenamidfumarat; TFV = tenofovir
English: Table 2: Interactions between the individual components of Descovy and other medicinal products
Croatian: Tablica 2: Interakcije između pojedinih komponenti lijeka Descovy i drugih lijekova Lijekovi prema terapijskim područjima1
English: Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).
Croatian: U 144 tjedna liječenja nijedan ispitanik nije prekinuo primjenu E/C/F/TAF-a zbog štetnog događaja nastalog tijekom liječenja povezanog s funkcijom bubrega, u usporedbi s 12 ispitanika koji su prekinuli primjenu E/C/F/TDF-a (p < 0,001).
English: No dose adjustment of norgestimate/ethinylestradiol is required.
Croatian: Nije potrebna prilagodba doze norgestimata/etinilestradiola.
English: Antimycobacterials Rifabutin
Croatian: Antimikobakterijski lijekovi Rifabutin
English: If you forget to take Descovy
Croatian: Ako ste zaboravili uzeti lijek Descovy
English: Descovy should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations.
Croatian: Primjenu lijeka Descovy potrebno je izbjegavati u bolesnika s procijenjenim CrCl ≥ 15 ml/min i < 30 ml/min, ili < 15 ml/min koji nisu na kroničnoj hemodijalizi, jer sigurnost primjene lijeka Descovy u ovih populacija nije ustanovljena.
English: If you feel dizzy when taking Descovy, do not drive and do not use any tools or machines.
Croatian: Ako tijekom uzimanja lijeka Descovy imate omaglicu, nemojte upravljati vozilom niti raditi s alatima ili na strojevima.
English: 7 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposurers expected in HCV-infected patients.
Croatian: 7 Ispitivanje provedeno s dodatnom dozom voksilaprevira od 100 mg kako bi se postigle izloženosti voksilapreviru očekivane u bolesnika zaraženih HCV-om.
English: • lamivudine
Croatian: • lamivudin
English: In vitro Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.
Croatian: Smanjena osjetljivost na emtricitabin povezana je s M184V/I mutacijama u HIV-1 RT.
English: The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Croatian: Farmakokinetika emtricitabina nije ispitana u ispitanika s oštećenjem funkcije jetre; međutim emtricitabin se neznatno metabolizira putem enzima jetre, pa bi učinak oštećenja funkcije jetre trebao biti ograničen.
English: The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean in vitro IC90 value for anti-HIV-1 activity.
Croatian: Srednja vrijednost najniže koncentracije u plazmi pri dinamičkoj ravnoteži 24 sata nakon primjene doze bila je jednaka ili veća od srednje vrijednosti IC90 in vitro za anti-HIV-1 djelovanje.
English: It is not known whether tenofovir alafenamide is an inhibitor of other UGT enzymes.
Croatian: Nije poznato je li tenofoviralafenamid inhibitor drugih UGT enzima.
English: Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time.
Croatian: Iako uz Descovy nisu opažene tegobe s bubrezima, postoji mogućnost da Vam se jave tegobe s bubrezima ako uzimate Descovy tijekom dugog vremenskog razdoblja.
English: No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.
Croatian: Nije bio opažen antagonizam s emtricitabinom ili tenofoviralafenamidom kad su se kombinirali s drugim antiretrovirusnim lijekovima.
English: • anticonvulsants, used to treat epilepsy, such as: carbamazepine, oxcarbazepine, phenobarbital and phenytoin
Croatian: • antikonvulzive, primjenjuju se za liječenje epilepsije, kao što su: karbamazepin, okskarbazepin, fenobarbital i fenitoin
English: Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
Croatian: Tenofoviralafenamid se transportira P-glikoproteinom (P-gp) i proteinom rezistencije karcinoma dojke (BCRP).
English: At baseline, median eGFR was 56 mL/min, and 33% of patients had an eGFR from 30 to 49 mL/min.
Croatian: Medijan eGFR na početku iznosio je 56 ml/min, a 33% bolesnika imalo je eGFR od 30 do 49 ml/min.
English: Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture.
Croatian: Emtricitabin i tenofoviralafenamid pokazuju sinergističko antivirusno djelovanje u staničnoj kulturi.
English: Medicinal products that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption.
Croatian: Lijekovi koji jako utječu na aktivnost P-gp-a i BCRP-a mogu dovesti do promjena u apsorpciji tenofoviralafenamida.
English: Adults and adolescents aged 12 years and older, weighing at least 35 kg Descovy should be administered as shown in Table 1.
Croatian: Odrasli i adolescenti u dobi od 12 godina i stariji, s tjelesnom težinom od najmanje 35 kg Descovy se primjenjuje kako je prikazano u Tablici 1.
English: Do not stop taking Descovy without talking to your doctor.
Croatian: Nemojte prestati uzimati lijek Descovy bez prethodnog razgovora sa svojim liječnikom.
English: Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
Croatian: Descovy se u kombinaciji s drugim lijekovima primjenjuje za liječenje infekcije virusom humane imunodeficijencije 1 (HIV-1) u odraslih i adolescenata u dobi od 12 godina i starijih, koji imaju tjelesnu težinu od najmanje 35 kg.
English: There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen.
Croatian: Zabilježene su visoke stope virološkog neuspjeha i pojave rezistencije u ranoj fazi kad se tenofovirdizoproksil kombinirao s lamivudinom i abakavirom, kao i s lamivudinom i didanozinom, u režimu jedanput dnevno.
English: No emergent resistance to E/C/F/TAF was detected through Week 48.
Croatian: Do kraja 48. tjedna nije bila otkrivena pojava rezistencije na E/C/F/TAF.
English: Dose Descovy according to the concomitant antiretroviral (see section 4.2).
Croatian: Dozirati Descovy ovisno o istodobno primjenjivanim antiretrovirusnim lijekovima (vidjeti dio 4.2).
English: Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.
Croatian: Descovy se ne smije primjenjivati istodobno s lijekovima koji sadržavaju tenofoviralafenamid, tenofovirdizoproksil, emtricitabin, lamivudin ili adefovirdipivoksil.
English: Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50% fat) resulted in a decrease in tenofovir alafenamide Cmax (15-37%) and an increase in AUClast (17-77%).
Croatian: U odnosu na stanje natašte, primjena tenofoviralafenamida s visokomasnim obrokom (~800 kcal, 50% masti) uzrokovala je smanjenje Cmax (15-37%) i povećanje AUCzadnji (17-77%) tenofoviralafenamida.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment.
Croatian: Autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa) također su zabilježeni u sklopu imunološke reaktivacije; međutim, prijavljeno vrijeme do nastupa poremećaja više varira i ti događaji mogu se pojaviti puno mjeseci nakon početka liječenja.
English: Do not use this medicine after the expiry date which is stated on the carton and bottle after “EXP”.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i boci iza oznake „Rok valjanosti“.
English: Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 in vitro.
Croatian: Tenofoviralafenamid nije inhibitor ljudske uridin-difosfat-glukuronoziltransferaze (UGT) 1A1 in vitro.
English: On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment.
Croatian: Na dane hemodijalize, Descovy treba primijeniti nakon završetka postupka hemodijalize.
English: The mean age was 58 years (range: 24-82), with 63 patients (26%) who were ≥ 65 years of age.
Croatian: Srednja vrijednost dobi bila je 58 godina (raspon: 24-82), sa 63 bolesnika (26%) u dobi ≥ 65 godina.
English: Do not breast-feed during treatment with Descovy.
Croatian: Nemojte dojiti tijekom liječenja lijekom Descovy.
English: Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food Do not chew, crush or split the tablet.
Croatian: Adolescenti u dobi od 12 godina i stariji, koji imaju tjelesnu težinu najmanje 35 kg: jedna tableta svaki dan, s hranom ili bez nje.
English: 1 With the exception of angioedema, anaemia and urticaria (see footnotes 2, 3 and 4), all adverse reactions were identified from clinical studies of F/TAF containing products.
Croatian: 1 Osim angioedema, anemije i urtikarije (vidjeti podnožne bilješke 2, 3 i 4), sve su nuspojave bile utvrđene u kliničkim ispitivanjima lijekova koji sadrže F/TAF.
English: Of the patients who were HBeAg positive at baseline, 1/30 (3.3%) achieved seroconversion to anti-HBe at Week 48.
Croatian: Od bolesnika koji su na početku bili HBeAg pozitivni, 1/30 (3,3%) postiglo je serokonverziju u anti-HBe u 48. tjednu.
English: PI = protease inhibitor a Week 48 window was between Day 294 and 377 (inclusive).
Croatian: IP = inhibitor proteaze a Okvir 48. tjedna bio je između 294. i 377. dana (uključivo).
English: Discontinuation of Descovy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Croatian: Prekid terapije lijekom Descovy u bolesnika istodobno zaraženih HIV-om i HBV-om može biti povezan s teškim akutnim egzacerbacijama hepatitisa.
English: In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.
Croatian: U nekih bolesnika s uznapredovalom bolešću jetre ili cirozom jetre prekid liječenja može dovesti do pogoršanja hepatitisa, što može biti opasno po život.
English: Bone toxicity was observed as reduced BMD in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Descovy.
Croatian: Toksičnost za kost uočena je kao smanjeni BMD u štakora i pasa pri izloženostima tenofoviru najmanje četiri puta većima od onih očekivanih nakon primjene lijeka Descovy.
English: In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 μg/mL.
Croatian: In vitro vezanje emtricitabina za humane proteine plazme bilo je < 4% i nije ovisilo o koncentraciji u rasponu od 0,02-200 µg/ml.
English: Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs Week 48.
Croatian: Od bolesnika koji su na početku bili HBsAg pozitivni, 3/70 (4,3%) postiglo je serokonverziju u anti-HBs u 48. tjednu.
English: • herbal remedies used to treat depression and anxiety containing: St. John's wort (Hypericum perforatum)
Croatian: • biljne lijekove, primjenjuju se za liječenje depresije i tjeskobe, a koji sadržavaju: gospinu travu (Hypericum perforatum)
English: Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply.
Croatian: Descovy koči djelovanje enzima reverzne transkriptaze koji je nužan za umnažanje virusa.
English: Patients with HIV-1 harbouring mutations
Croatian: Bolesnici s HIV-1 koji nosi mutacije
English: When your supply of Descovy starts to run low, get more from your doctor or pharmacist.
Croatian: Kad Vam se smanji zaliha lijeka Descovy, nabavite još lijeka od liječnika ili ljekarnika.
English: The adverse reactions in Table 3 are listed by system organ class and frequency.
Croatian: Nuspojave u Tablici 3 navedene su prema klasifikaciji organskih sustava i učestalosti.
English: No dose adjustment of Descovy is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.
Croatian: Nije potrebna prilagodba doze lijeka Descovy u odraslih ili adolescenata (u dobi od najmanje 12 godina i s tjelesnom težinom od najmanje 35 kg) s procijenjenim klirensom kreatinina (CrCl) ≥ 30 ml/min.
English: Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).
Croatian: Lijek Descovy je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih osoba i adolescenata (u dobi od 12 godina i starijih, s tjelesnom težinom od najmanje 35 kg) zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1) (vidjeti dijelove 4.2 i 5.1).
English: The safety profile in patients with mild to moderate renal impairment was similar to that in patients with normal renal function (see section 5.1).
Croatian: Sigurnosni profil u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega bio je sličan onome u bolesnika s normalnom funkcijom bubrega (vidjeti dio 5.1).
English: Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro.
Croatian: Tenofoviralafenamid nije inhibitor CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ili CYP2D6 in vitro.
English: The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), St. John's wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5).
Croatian: Ne preporučuje se istodobna primjena lijeka Descovy s određenim antikonvulzivima (npr. karbamazepinom, okskarbazepinom, fenobarbitalom i fenitoinom), antimikobakterijskim lijekovima (npr. rifampicinom, rifabutinom, rifapentinom), gospinom travom i inhibitorima proteaze HIV-a osim atazanavirom, lopinavirom i darunavirom (vidjeti dio 4.5).
English: No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide.
Croatian: Klinički značajne farmakokinetičke razlike vezane uz dob, spol ili etničku pripadnost nisu ustanovljene za emtricitabin ili tenofoviralafenamid.